Improvement in bone strength parameters. The role of strontium ranelate

Journal of Musculoskeletal Neuronal Interactions

Volumn 7, Issue 3, 2007, Pages 266-267

  Tournis, S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bone strength; Postmenopausal osteoporosis; Strontium ranelate

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBONATE DEHYDRATASE; FIBRONECTIN RECEPTOR; PARATHYROID HORMONE[1-34]; STRONTIUM RANELATE;

BONE DENSITY; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CELL DIFFERENTIATION; CONFERENCE PAPER; DRUG MECHANISM; IN VITRO STUDY; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; X RAY MICROANALYSIS;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; BONE RESORPTION; DISEASE MODELS, ANIMAL; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; RATS; THIOPHENES; TREATMENT OUTCOME; WEIGHT-BEARING;

EID: 36949000280     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. American Association of Clinical Endocrinologist Medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocrine Practice 2001; 7:293-312.
2. Seeman F, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354:2250-2261.
3. Riggs LE, Parfitt MA. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005; 20:177-184.
4. Marie PJ. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. Osteoporos Int 2003; 14 (Suppl.3):S9-S12.
5. Tournis S, Economopoulos D, Lyritis GP. Strontium Ranelate: a novel treatment in postmenopausal osteoporosis. Ann NY Acad Sci 2006; 1092:403-407.
6. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PT. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996; 18:517-523.
7. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002; 450:11-17
8. Takahashi N, Sasaki T, Tsouderos Y, Suda T. S12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003; 18:1082-1087.
9. Marie PJ, Hott M, Modrowski D, De Pollack C, Guillemain J, Deloffre P, Tsouderos Y. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen deficient rats. J Bone Miner Res 1993; 8:607-615
10. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 2004; 19:2012-2020.
11. Amman P, Badoud I, Shen V, Bain S, Dupin-Roger I, Rizzoli R. Strontium ranelate prevents alteration of bone strength in OVX rats by improving intrinsic bone tissue quality. Osteoporos Int 2006; 17(Suppl.2):S93.
12. Hott M, Deloffre P, Tsouderos Y, Marie PJ. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 2003; 33:115-123.
13. Farlay D, Boivin G, Panczer G, Lalande A, Meunier PJ. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res 2005; 20:1569-1578.